Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 9,200 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock in a transaction on Tuesday, April 21st. The stock was sold at an average price of $23.00, for a total transaction of $211,600.00. Following the completion of the transaction, the chief financial officer directly owned 145,355 shares of the company’s stock, valued at $3,343,165. The trade was a 5.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ivan Hyep also recently made the following trade(s):

• On Monday, March 23rd, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.52, for a total value of $170,384.00.
• On Wednesday, March 4th, Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.25, for a total value of $54,074.75.
• On Tuesday, March 3rd, Ivan Hyep sold 13,555 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.22, for a total value of $246,972.10.
• On Thursday, January 22nd, Ivan Hyep sold 1,882 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.15, for a total value of $34,158.30.

Bicara Therapeutics Stock Performance

Shares of Bicara Therapeutics stock opened at $23.63 on Thursday. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -9.34 and a beta of -1.23. The stock has a 50 day moving average price of $19.16 and a 200-day moving average price of $17.72. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $24.25.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.04. Sell-side analysts predict that Bicara Therapeutics Inc. will post -2.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Citizens Jmp reaffirmed a “market outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Bank of America began coverage on shares of Bicara Therapeutics in a research report on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price objective on the stock. HC Wainwright raised their price objective on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Wednesday, April 8th. Finally, BTIG Research reiterated a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $28.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BCAX. Vestal Point Capital LP lifted its holdings in Bicara Therapeutics by 2.0% during the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock valued at $80,529,000 after buying an additional 100,000 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Bicara Therapeutics by 596.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after acquiring an additional 2,771,868 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Bicara Therapeutics during the fourth quarter valued at approximately $44,484,000. Vanguard Group Inc. grew its stake in Bicara Therapeutics by 9.8% in the third quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock worth $34,753,000 after purchasing an additional 195,667 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Bicara Therapeutics by 179.5% in the 4th quarter. State Street Corp now owns 1,649,537 shares of the company’s stock worth $27,762,000 after buying an additional 1,059,260 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.